Cross Country Healthcare (CCRN) EGM 2026 summary
Event summary combining transcript, slides, and related documents.
EGM 2026 summary
17 Jul, 2026Opening remarks and agenda
Meeting called to order by CEO and Chairman, emphasizing inclusivity via virtual format.
Business portion conducted first, followed by a Q&A session.
Introduction of board members, executive officers, legal counsel, and inspector of elections.
Guidelines for orderly conduct and voting procedures outlined.
Specific resolutions to be voted on
Proposal to adopt the merger agreement, merging the company into a wholly owned subsidiary.
Advisory vote on compensation for named executive officers related to the merger.
Proposal to adjourn the meeting if more proxies are needed for the merger vote.
Corporate governance
Quorum established with 72% of voting power represented.
Inspector of elections sworn in and procedures for voting and questions explained.
Record date and notice procedures confirmed, with 32,306,484 shares outstanding.
Latest events from Cross Country Healthcare
- Q3 2024 revenue fell 29% year-over-year, with margin pressure but strong cash and diversification.CCRN
Q3 20248 Jul 2026 - Q2 revenue dropped 37% with a net loss, but cash flow and liquidity remain strong.CCRN
Q2 20248 Jul 2026 - Shareholders to vote on a $13.25 per share cash merger, with board unanimous support.CCRN
Proxy filing15 Jun 2026 - Shareholders to receive $13.25 per share in cash in a board-approved merger, pending approvals.CCRN
Proxy filing3 Jun 2026 - Q1 2026 revenue dropped 17.8% and net loss widened, as merger plans to go private were announced.CCRN
Q1 20268 May 2026 - Shareholders to vote on $437M all-cash acquisition by Knox Lane, with no operational changes expected.CCRN
Proxy filing7 May 2026 - Transition to private ownership by Knox Lane at $13.25 per share, pending shareholder approval.CCRN
Proxy filing7 May 2026 - Acquisition by Knox Lane will take the company private, focusing on value and continuity.CCRN
Proxy filing7 May 2026 - All shares to be acquired for $13.25 cash in a $437M deal, pending shareholder approval.CCRN
Proxy filing7 May 2026